Kopion Asset Management purchased 327,064 additional shares of Certara (worth ~$3.37 million) during Q4, despite the stock falling 23% post-earnings. The fund views the sharp decline as a buying opportunity, noting that Certara's underlying business remains solid with 10% revenue growth and improved profitability, making it an attractive entry point for disciplined investors.

Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.

The global In Silico Clinical Trials Market is projected to grow from $3.42 billion in 2023 to $6.68 billion by 2032, driven by AI-based modeling, regulatory support, and accelerated drug development strategies.

Certara launches AI-powered Quantitative Systems Pharmacology (QSP) platform called Certara IQ, highlighting the company's technological innovation in drug development. The company also celebrates its scientific achievements with 200 published papers and 11 scientists recognized among top cited researchers.

Certara, a biosimulation technology company, will release its third quarter 2025 financial results on November 6th, hosting a conference call at 5:00 PM ET for investors.

Certara introduces Pinnacle 21 Enterprise Plus, a software solution that helps clinical and statistical programmers efficiently create and manage data specifications for regulatory submissions, promising a 50% reduction in time spent drafting mapping specifications.

The global biosimulation market is expected to grow from USD 3.97 billion in 2024 to USD 18.97 billion by 2034, with a CAGR of 16.9%. North America currently dominates the market, driven by technological advancements and increasing research in drug development and discovery.

Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.

Three companies in the software-based drug development and furniture industries have emerged as momentum plays following a period of market volatility. Certara, Schrodinger, and Lovesac have seen their stock prices rise significantly due to positive news, technological advancements, and adaptable business models.

Several mid-cap stocks outperformed the market during the volatile week of April 7-11, including AeroVironment, Recursion Pharmaceuticals, Certara, and Agilon Health. The gains were driven by factors such as FDA reforms, tariff pauses, and positive news for the companies.

The FDA announced a major shift towards adopting human-relevant and technologically advanced testing methods, including AI-based simulations and lab-grown organoids, to evaluate monoclonal antibody therapies and other drugs, reducing the reliance on traditional animal testing.

The biosimulation market is projected to reach USD 9.18 billion by 2029, growing at a CAGR of 16.7% from 2024 to 2029. The market is driven by the increasing need for cost and time reduction in the drug development process, but high costs of biosimulation technologies remain a restraint.